• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»lorlatinib

From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026

By Pallavi Madhiraju on April 22, 2026   Pharma & Biotech  

From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026

Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.

Recent Posts

  • What TG Therapeutics, Inc.’s AAN 2026 updates reveal about real-world performance of BRIUMVI in multiple sclerosis
  • Why CervoMed Inc.’s neflamapimod findings may reshape biomarker-driven trials in dementia with Lewy bodies
  • Can Neurona Therapeutics validate regenerative cell therapy in epilepsy with Phase 3 EPIC trial
  • What Tempest Therapeutics, Inc.’s CAR-T strategy reveals about the next phase of cell therapy competition
  • Can CARTOSOUND SONATA help Johnson & Johnson tighten its grip on electrophysiology workflow?
  • Why Star Therapeutics’ FDA win for VGA039 could reshape the von Willebrand disease treatment race.
  • Can Alto Neuroscience turn an overlooked Parkinson’s drug into a major depression breakthrough?
  • Artera’s EU breakthrough in AI cancer testing opens a bigger battle over workflow, trust, and scale
  • Can Forlong Biotechnology’s FL115 poster at ASCO 2026 move the IL-15 story from scientific promise toward clinical relevance?
  • Incyte brings Phase 3 tafasitamab data to ASCO 2026, but will frontMIND reshape first-line DLBCL treatment?
  • Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?
  • Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes